NO20062377L - CCR-2-antagonistsalt - Google Patents

CCR-2-antagonistsalt

Info

Publication number
NO20062377L
NO20062377L NO20062377A NO20062377A NO20062377L NO 20062377 L NO20062377 L NO 20062377L NO 20062377 A NO20062377 A NO 20062377A NO 20062377 A NO20062377 A NO 20062377A NO 20062377 L NO20062377 L NO 20062377L
Authority
NO
Norway
Prior art keywords
antagonistsalt
ccr
succinate salt
methoxytetrahydro
naphthyridin
Prior art date
Application number
NO20062377A
Other languages
English (en)
Inventor
Daniel Richard Sidler
Mark Jensen
Robert Lasen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20062377L publication Critical patent/NO20062377L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveie-bringer en effektiv syntese for fremstilling av ((IR,3S)-3-isopropyl-3-{[3-(trifluormetyl)-7,8-dihydro-l,6-naftyridin-6(5H)-yl]karbonyl}syklo-pentyl) [(3S, 4S)-3-metoksytetrahydro-2H-pyran-4-yl]amin og dets sukkinat-salt. Foreliggende oppfinnelse tilveiebringer i tillegg en effektiv syntese for fremstilling av mellomproduktene (3R)-3-metoksytetrahydro-4H-pyran-4-on; (IS,4S)-4-(2,5-dimetyl-lH-pyrrol-1-yl)-1-isopropyl-syklopent-2-en-l-karboksylsyre; og 3-(trifluormetyl)-5,6,7,8-tetrahydro-1,6-naftyridin; og for fremstilling av forløperen (3S,4S)-N-((IS,4S)-4-isopropyl-4-{[3-(trifluormetyl)-7,8-dihydro-1,6-naftyridin-6(5H)-yl]karbonyl }syklopent-2-en-l-yl)-3-metoksy-tetrahydro-2H-pyran-4-amin. Oppfinnelsen ligger enn videre i tillegg i de glimrende egenskaper av sukkinat-saltet av ((IR,3S)-3-isopropyl-3-{[3-(trifluormetyl)-7,8-dihydro-l,6-naftyridin-6(5H)-yl]karbonyl}syklo-pentyl) [(3S, 4S)-3-metoksytetrahydro-2H-pyran-4-yl]amin.
NO20062377A 2003-10-27 2006-05-24 CCR-2-antagonistsalt NO20062377L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27
PCT/US2004/035069 WO2005044264A1 (en) 2003-10-27 2004-10-25 Ccr-2 antagonist salt

Publications (1)

Publication Number Publication Date
NO20062377L true NO20062377L (no) 2006-05-24

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062377A NO20062377L (no) 2003-10-27 2006-05-24 CCR-2-antagonistsalt

Country Status (21)

Country Link
US (1) US7473696B2 (no)
EP (1) EP1682135B1 (no)
JP (1) JP4542550B2 (no)
KR (1) KR20060101476A (no)
CN (1) CN1870998B (no)
AT (1) ATE517622T1 (no)
AU (1) AU2004287416C1 (no)
BR (1) BRPI0415836A (no)
CA (1) CA2543201C (no)
CO (1) CO5690606A2 (no)
EC (1) ECSP066524A (no)
IL (1) IL175009A0 (no)
IS (1) IS8400A (no)
MA (1) MA28104A1 (no)
MX (1) MXPA06004647A (no)
NO (1) NO20062377L (no)
NZ (1) NZ546447A (no)
RU (1) RU2317295C1 (no)
UA (1) UA81365C2 (no)
WO (1) WO2005044264A1 (no)
ZA (1) ZA200602752B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004050024A2 (en) 2002-11-27 2004-06-17 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2004082616A2 (en) * 2003-03-18 2004-09-30 Merck & Co. Inc. Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
CA2550596C (en) 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
AP2006003849A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
EP2962691A4 (en) 2013-02-28 2016-08-31 Santen Pharmaceutical Co Ltd AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2787790A1 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
US6500844B1 (en) * 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2002013824A1 (en) * 2000-08-17 2002-02-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
MXPA03004714A (es) * 2000-11-28 2003-08-19 Pfizer Prod Inc Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JP3780291B2 (ja) * 2002-04-29 2006-05-31 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤
CA2483843A1 (en) * 2002-04-29 2003-11-13 Merck & Co. Inc. Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
WO2005044264A1 (en) 2005-05-19
ATE517622T1 (de) 2011-08-15
NZ546447A (en) 2009-02-28
ECSP066524A (es) 2006-10-10
CN1870998A (zh) 2006-11-29
EP1682135A1 (en) 2006-07-26
JP2007509940A (ja) 2007-04-19
AU2004287416C1 (en) 2010-09-09
IS8400A (is) 2006-04-06
EP1682135B1 (en) 2011-07-27
AU2004287416A1 (en) 2005-05-19
MXPA06004647A (es) 2006-06-27
JP4542550B2 (ja) 2010-09-15
IL175009A0 (en) 2006-08-20
AU2004287416B2 (en) 2009-11-19
UA81365C2 (en) 2007-12-25
CO5690606A2 (es) 2006-10-31
CN1870998B (zh) 2010-10-20
CA2543201C (en) 2010-12-21
CA2543201A1 (en) 2005-05-19
EP1682135A4 (en) 2009-11-25
RU2317295C1 (ru) 2008-02-20
US7473696B2 (en) 2009-01-06
MA28104A1 (fr) 2006-08-01
KR20060101476A (ko) 2006-09-25
US20070135474A1 (en) 2007-06-14
BRPI0415836A (pt) 2007-01-02
ZA200602752B (en) 2007-08-29

Similar Documents

Publication Publication Date Title
IS8400A (is) CCR-2 mótlyfssalt
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
IL171170A (en) History of itensinoids and their pharmaceutical preparations, methods of preparation and use thereof
IL169690A0 (en) Uses of anti-insulin-like growth factor i receptor antibodies
AU2002246728A1 (en) Carboline derivatives
WO2006034039A3 (en) Substituted morphinans and methods of their use
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
MY146564A (en) Aza-substituted spiro derivatives
PL1622569T3 (pl) Pochodne aza spiro alkanów jako inhibitory metaloproteaz
AU2002249890A1 (en) Carboline derivatives
JO2400B1 (en) Polyethylene glycol derivatives
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
AU2003266132A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 4,5-dihydroimidazo(1,4,5-de)benzoxazine
AR045875A1 (es) Procedimiento para la preparacion del antagonista ccr-2
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
DE60008400D1 (de) Triazolopyrimidinderivate
EP1786815A4 (en) SPIRO COMPOUNDS AND METHOD FOR MODULATING CHEMOKIN RECEPTOR ACTIVITY
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
AU2002357417A1 (en) Drug compositions with indole alkaloids for the treatment of aids
HK1102809A (en) Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application